Brian I Rini

发表

Renal cell carcinoma

B. Rini, S. Campbell, B. Escudier, 2009, The Lancet.

Combination immunotherapy with prostatic acid phosphatase pulsed antigen‐presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy

E. Small, B. Rini, R. Hershberg, 2006, Cancer.

Prospective Clinical Study of Precision Oncology in Solid Tumors.

Gary W Procop, Jame Abraham, A. Khorana, 2015, Journal of the National Cancer Institute.

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Wanling Xie, Tina Cheng, Michael B Atkins, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical factors associated with outcome in patients with metastatic clear‐cell renal cell carcinoma treated with vascular endothelial growth factor‐targeted therapy

T. Choueiri, B. Rini, R. Bukowski, 2007, Cancer.

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.

E. Plimack, M. Voss, P. Sharma, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Resistance to targeted therapy in renal-cell carcinoma.

Michael B Atkins, M. Atkins, B. Rini, 2009, The Lancet. Oncology.

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

John Smeraglia, R. Motzer, M. Michaelson, 2007, Journal of Translational Medicine.

Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference

Mark A Rosen, Michael B Atkins, Keith T Flaherty, 2007, Clinical Cancer Research.

Vascular endothelial growth factor‐targeted therapy in metastatic renal cell carcinoma

B. Rini, Brian I Rini, 2009, Cancer.

Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma.

Keith Flaherty, K. Flaherty, B. Rini, 2008, Urologic oncology.

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.

Keith T Flaherty, Paul S Meltzer, Maria J Merino, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results.

W Marston Linehan, W. Linehan, R. Srinivasan, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin

B. Rini, Brian I Rini, 2008, Clinical Cancer Research.

Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity.

Antonio Lopez-Beltran, Alexander Kutikov, Andrew J Armstrong, 2015, European urology.

Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.

Shetal N Shah, Erick M Remer, B. Rini, 2010, AJR. American journal of roentgenology.

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

R. Figlin, R. Motzer, M. Michaelson, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.